Edition:
United Kingdom

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

6.89USD
17 Aug 2018
Change (% chg)

$-0.02 (-0.29%)
Prev Close
$6.91
Open
$6.90
Day's High
$6.95
Day's Low
$6.79
Volume
175,929
Avg. Vol
230,070
52-wk High
$8.05
52-wk Low
$2.27

Chart for

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $329.60
Shares Outstanding(Mil.): 109.14
Dividend: --
Yield (%): --

Financials

  CERS.OQ Industry Sector
P/E (TTM): -- 32.30 32.76
EPS (TTM): -0.61 -- --
ROI: -83.14 13.94 14.61
ROE: -111.57 16.79 16.33

BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets

* CERUS ANNOUNCES HEALTH CANADA APPROVAL OF THE INTERCEPT BLOOD SYSTEM FOR PLATELETS Source text for Eikon: Further company coverage:

25 Apr 2018

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

02 Apr 2018

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

13 Mar 2018

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

08 Mar 2018

Competitors

  Price Chg
Terumo Corp (4543.T) ¥5,900 +180.00
Grifols SA (GRLS.MC) €24.55 +0.48
Grifols SA (GRLSbn.MC) €17.76 +0.06

Earnings vs. Estimates